FDA Approves ValloVax™ for Clinical Investigation…But It’s Available at CHIPSA Now
The United States Food and Drug Administration has just cleared Batu Biologic’s, new immunotherapy, ValloVax™ into clinical trials for certain solid tumors.
They Are Currently Using It At CHIPSA
This is the first therapy that targets the blood vasculature feeding the tumors that has received an investigational new drug (IND) approval from the FDA. This decision by the FDA will allow Batu Biologics to initiate Phase 1 clinical trials here in the United States, although they have already been administering ValloVax™ at CHIPSA.
In previous studies that used animal models, Batu showed the efficacy of ValloVax in some lung, colon, breast, brain, and skin cancers.
“It is our hope that ValloVax™ , our novel immune therapy, will treat cancer by training the immune system to kill tumor-associated blood vessels,” said Alan Lewis, PhD, chairman of Batu Biologics. “Blood vessel formation is associated with malignancy and metastatic activity in established tumors, and ValloVax™ may have clinical benefit in treating multiple cancers.”
How ValloVax™ Works
Batu Biologics has developed a novel approach to fighting cancer through immune stimulation, by focusing on the tumor endothelium. By targeting multiple proteins found on the tumor-associated blood vessels, ValloVax™ seeks to target and prevent tumor angiogenesis
Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels. In tumors this mean new blood vessels “feed” growing tumors with oxygen and nutrients, allowing the cancer cells to invade nearby tissue, to move throughout the body, and to form new colonies of cancer cells, called metastases.
By targeting the tumor endothelium Vallovax accomplishes the following:
- No mutation means that the blood vessels around the tumor do not develop drug resistance.
- Without angiogenesis, or the formation of new blood vessels, the tumor cannot exceed 1 to 2 mm in diameter.
- The tumor endothelium is in direct contact with the body’s immune system, addressing the issue of drug delivery to hypoxic areas of the tumor.
Below is an image that shows the mechanism of action of the ValloVax induced immune response:
ValloVax works by inducing a comprehensive immune response (mediated by both immune cells and antibodies) against the cancer blood vessels, while leaving healthy blood vessels unharmed.
Current angiogenesis inhibitors, such as Avastin, target only one of the key pathways of angiogenesis (VEGF).
ValloVax on the other hand stimulates the immune system to attack various pathways necessary for angiogenesis, which may give it a better potential when compared to existing cancer drugs.
What The Future Holds
With the recent successes of immunotherapy in a variety of tumors, CHIPSA and Batu Biologics believe there is an increasing need for non-toxic options. Our Team is excited to bring immunotherapy to the forefront of medical research and to use the power of the body’s own immune system to extend life expectancy.
If you or someone you love would like to see how or if you can utilize Vallovax for cancer give us a call at 1-855-624-4772 or click the button below. We will schedule you a free 30 minute appointment to talk to one of our doctors.Click Here To Speak With a Doctor For Free!